2025-07-31
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today is pleased to announce preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China.
View more
2025-07-02
IMM2510/AXN-2510 receives FDA IND clearance for phase 1b/2 trial
SHANGHAI and DALLAS,TX, July 2, 2025 (GLOBE NEWSWIRE)– ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”) and Instil Bio, Inc. (Nasdaq: TIL, "Instil") , today announced the clearance of an Investigational New Drug (IND) application for IMM2510/AXN-2510 by the U.S. Food and Drug Administration.
View more
2025-05-15
The National Medical Products Administration (NMPA) Approved ImmuneOnco’s Clinical Trial Application for Tazlestobart (IMM27M) Combined with Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Squamous Non-Sma
On May 15, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as “ImmuneOnco,” Hong Kong Stock Exchange stock code: 01541.HK) announced that the Phase Ib/II clinical trial application fo
View more
